OS Results of a Study Evaluating Dabrafenib and Trametinib in Melanoma

Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussy in Paris, discusses overall survival (OS) results of a recent study evaluating dabrafenib and trametinib in melanoma.